Approved for JALYN is a combination of dutasteride, a 5-alpha-reductase inhibitor, and tamsulosin, an alpha-adrenergic antagonist, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. ( 1.1 ) Limitations of Use: Dutasteride-containing products, including JALYN, are not approved for the prevention of prostate cancer. ( 1.2 ). JALYN is a…
Loading full data from Know Your Drugs Institute…